Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease

Alpha-synuclein is a presynaptic protein expressed throughout the central nervous system, and it is the main component of Lewy bodies, one of the histopathological features of Parkinson's disease (PD) which is a progressive and irreversible neurodegenerative disorder. The conformational flexibility of α-synuclein allows it to adopt different conformations, i.e., bound to membranes or form aggregates, the oligomers are believed to be the more toxic species. In this review, we will focus on two major features of α-synuclein, transmission and toxicity, that could help to understand the pathological characteristics of PD. One important feature of α-synuclein is its ability to be transmitted from neuron to neuron using mechanisms such as endocytosis, plasma membrane penetration or through exosomes, thus propagating the Lewy body pathology to different brain regions thereby contributing to the progressiveness of PD. The second feature of α-synuclein is that it confers cytotoxicity to recipient cells, principally when it is in an oligomeric state. This form causes mitochondrial dysfunction, endoplasmic reticulum stress, oxidative stress, proteasome impairment, disruption of plasma membrane and pore formation that lead to apoptosis pathway activation and consequent cell death. The complexity of α-synuclein oligomerization and formation of toxic species could be a major factor for the irreversibility of PD and could also explain the lack of successful therapies to halt the disease.

[1]  E. Junn,et al.  Human α-Synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine , 2002, Neuroscience Letters.

[2]  Samrat Mukhopadhyay,et al.  Structural and Dynamical Insights into the Membrane-Bound α-Synuclein , 2013, PloS one.

[3]  G. Bernardi,et al.  The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy? , 2005, Trends in pharmacological sciences.

[4]  Michael Wolff,et al.  Seeding induced by α‐synuclein oligomers provides evidence for spreading of α‐synuclein pathology , 2009, Journal of neurochemistry.

[5]  E. Masliah,et al.  Dynamics of α‐synuclein aggregation and inhibition of pore‐like oligomer development by β‐synuclein , 2007 .

[6]  Y. Itoyama,et al.  Plasma membrane ion permeability induced by mutant α‐synuclein contributes to the degeneration of neural cells , 2006, Journal of neurochemistry.

[7]  N. Inestrosa,et al.  β-Amyloid Causes Depletion of Synaptic Vesicles Leading to Neurotransmission Failure* , 2009, The Journal of Biological Chemistry.

[8]  P. Brundin,et al.  α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. , 2011, The Journal of clinical investigation.

[9]  C. Lavedan The synuclein family. , 1998, Genome research.

[10]  Claudio Soto,et al.  Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. , 2011, Seminars in cell & developmental biology.

[11]  K. Bötzel,et al.  Single-Channel Electrophysiology Reveals a Distinct and Uniform Pore Complex Formed by α-Synuclein Oligomers in Lipid Membranes , 2012, PloS one.

[12]  Sanjeev Gupta,et al.  Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders , 2011, Journal of cellular and molecular medicine.

[13]  A. Björklund,et al.  Alpha-Synuclein Cell-to-Cell Transfer and Seeding in Grafted Dopaminergic Neurons In Vivo , 2012, PloS one.

[14]  S. Lindquist,et al.  α-Synuclein: membrane interactions and toxicity in Parkinson's disease. , 2010, Annual review of cell and developmental biology.

[15]  J. Trojanowski,et al.  Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies , 2013, Nature Reviews Neuroscience.

[16]  Claudio Soto,et al.  Unfolding the role of protein misfolding in neurodegenerative diseases , 2003, Nature Reviews Neuroscience.

[17]  M. Parihar,et al.  Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells. , 2009, The international journal of biochemistry & cell biology.

[18]  Mathias Jucker,et al.  Self-propagation of pathogenic protein aggregates in neurodegenerative diseases , 2013, Nature.

[19]  R. Edwards,et al.  The Function of α-Synuclein , 2013, Neuron.

[20]  J. Jankovic Parkinson’s disease: clinical features and diagnosis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[21]  P. Spano,et al.  From α-synuclein to synaptic dysfunctions: New insights into the pathophysiology of Parkinson's disease , 2012, Brain Research.

[22]  J. Troncoso,et al.  Endoplasmic Reticulum Stress Is Important for the Manifestations of α-Synucleinopathy In Vivo , 2012, The Journal of Neuroscience.

[23]  E. Masliah,et al.  The many faces of α-synuclein: from structure and toxicity to therapeutic target , 2012, Nature Reviews Neuroscience.

[24]  H. Shill,et al.  Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains , 2013, Experimental Neurology.

[25]  R. Benz,et al.  Structural properties of pore-forming oligomers of alpha-synuclein. , 2009, Journal of the American Chemical Society.

[26]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Parodi,et al.  Pore- Forming Neurotoxin-Like Mechanism for A b Oligomer-Induced Synaptic Failure , 2009 .

[28]  Giuseppe Battaglia,et al.  Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Elisabet Englund,et al.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.

[30]  Smita Patel,et al.  Intravesicular Localization and Exocytosis of α-Synuclein and its Aggregates , 2005, The Journal of Neuroscience.

[31]  Brian Spencer,et al.  Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.

[32]  S. Arawaka,et al.  The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson’s disease: a review of in vivo models , 2013, Reviews in the neurosciences.

[33]  A. Bertolotti,et al.  Propagation of the prion phenomenon: beyond the seeding principle. , 2012, Journal of molecular biology.

[34]  Ji-Eun Suk,et al.  Non‐classical exocytosis of α‐synuclein is sensitive to folding states and promoted under stress conditions , 2010, Journal of neurochemistry.

[35]  L. Aguayo,et al.  Extracellular α‐synuclein alters synaptic transmission in brain neurons by perforating the neuronal plasma membrane , 2015, Journal of neurochemistry.

[36]  Tapan P. Patel,et al.  Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death , 2011, Neuron.

[37]  François-Xavier Theillet,et al.  Efficient modification of alpha-synuclein serine 129 by protein kinase CK1 requires phosphorylation of tyrosine 125 as a priming event. , 2014, ACS chemical neuroscience.

[38]  Neha Singh,et al.  Advances in the treatment of Parkinson's disease , 2007, Progress in Neurobiology.

[39]  J. Troncoso,et al.  Accumulation of Toxic α-Synuclein Oligomer within Endoplasmic Reticulum Occurs in α-Synucleinopathy In Vivo , 2012, The Journal of Neuroscience.

[40]  C. Ross,et al.  Protein aggregation and neurodegenerative disease , 2004, Nature Medicine.

[41]  C. Zurzolo,et al.  The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration. , 2013, The Biochemical journal.

[42]  Ad Bax,et al.  Structure and Dynamics of Micelle-bound Human α-Synuclein* , 2005, Journal of Biological Chemistry.

[43]  J. Trojanowski,et al.  Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells , 2009, Proceedings of the National Academy of Sciences.

[44]  Armin Giese,et al.  Different Species of α-Synuclein Oligomers Induce Calcium Influx and Seeding , 2007, The Journal of Neuroscience.

[45]  Claudio Soto,et al.  The intricate mechanisms of neurodegeneration in prion diseases. , 2011, Trends in molecular medicine.

[46]  Zeger Debyser,et al.  The remarkable conformational plasticity of alpha-synuclein: blessing or curse? , 2013, Trends in molecular medicine.

[47]  Chris Gardiner,et al.  Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission , 2011, Neurobiology of Disease.

[48]  S. Vicini,et al.  α‐Synuclein mediates alterations in membrane conductance: a potential role for α‐synuclein oligomers in cell vulnerability , 2010, The European journal of neuroscience.

[49]  A. O. Andrighetti,et al.  Alpha-synuclein pore forming activity upon membrane association. , 2012, Biochimica et biophysica acta.

[50]  M. Parihar,et al.  Mitochondrial association of alpha-synuclein causes oxidative stress , 2008, Cellular and Molecular Life Sciences.

[51]  C. Soto Transmissible Proteins: Expanding the Prion Heresy , 2012, Cell.

[52]  J. Trojanowski,et al.  Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice , 2012, The Journal of experimental medicine.

[53]  Ronald Melki,et al.  Neuron‐to‐neuron transmission of α‐synuclein fibrils through axonal transport , 2012, Annals of neurology.

[54]  P. Brundin,et al.  Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease. , 2009, Parkinsonism & related disorders.

[55]  C. Ross,et al.  Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. , 2005, Human molecular genetics.

[56]  O. Lindvall,et al.  Research in motion: the enigma of Parkinson's disease pathology spread , 2008, Nature Reviews Neuroscience.

[57]  T. Südhof,et al.  α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro , 2010, Science.

[58]  M. Farrer,et al.  Missing pieces in the Parkinson's disease puzzle , 2010, Nature Medicine.

[59]  Ssang-Goo Cho,et al.  Autophagic failure promotes the exocytosis and intercellular transfer of α-synuclein , 2013, Experimental & Molecular Medicine.

[60]  S. Koyama,et al.  Serine 129 phosphorylation of membrane-associated α-synuclein modulates dopamine transporter function in a G protein–coupled receptor kinase–dependent manner , 2013, Molecular biology of the cell.

[61]  C. Sigurdson,et al.  [Prion diseases?]. , 1985, Deutsche medizinische Wochenschrift.

[62]  M. Diamond,et al.  Prion-like mechanisms in neurodegenerative diseases , 2010, Nature Reviews Neuroscience.

[63]  E. Masliah,et al.  Role of α‐synuclein penetration into the membrane in the mechanisms of oligomer pore formation , 2012, The FEBS journal.

[64]  P. Brundin,et al.  A deadly spread: cellular mechanisms of α-synuclein transfer , 2011, Cell Death and Differentiation.

[65]  J. Trojanowski,et al.  Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice , 2012, Science.

[66]  Robert W. Peoples,et al.  Nature of the neurotoxic membrane actions of amyloid-β on hippocampal neurons in Alzheimer's disease , 2014, Neurobiology of Aging.

[67]  F. Tarazi,et al.  Emerging therapies for Parkinson's disease: from bench to bedside. , 2014, Pharmacology & therapeutics.

[68]  A. Winslow,et al.  Exosomal cell-to-cell transmission of alpha synuclein oligomers , 2012, Molecular Neurodegeneration.

[69]  Myeong-Hee Yu,et al.  Protein folding and diseases. , 2005, Journal of biochemistry and molecular biology.

[70]  J. Parodi,et al.  Synaptotoxicity of Alzheimer Beta Amyloid Can Be Explained by Its Membrane Perforating Property , 2010, PloS one.

[71]  S. Chandra,et al.  αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction , 2010, Proceedings of the National Academy of Sciences.

[72]  Anthony H V Schapira,et al.  Neurobiology and treatment of Parkinson's disease. , 2009, Trends in pharmacological sciences.

[73]  K. Chung,et al.  Amino acid sequence motifs and mechanistic features of the membrane translocation of α‐synuclein , 2006, Journal of neurochemistry.

[74]  L. Bubacco,et al.  Structural insights on physiological functions and pathological effects of ±‐synuclein , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[75]  Ruth Nussinov,et al.  Models of beta-amyloid ion channels in the membrane suggest that channel formation in the bilayer is a dynamic process. , 2007, Biophysical journal.

[76]  D. Allsop,et al.  Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[77]  L. Bubacco,et al.  Biophysical groundwork as a hinge to unravel the biology of α-synuclein aggregation and toxicity , 2014, Quarterly Reviews of Biophysics.